Skip to content

Periodic Continuous Glucose Monitoring in Patients With Type 2 Diabetes

Periodic Continuous Glucose Monitoring to Support a Person-centered Approach During Diabetes Consultations in Patients With Type 2 Diabetes- A Randomised Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05633628
Enrollment
400
Registered
2022-12-01
Start date
2023-02-01
Completion date
2026-12-01
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

CGM, Personcentered care

Brief summary

The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.

Detailed description

This is a 16-week prospective, multicenter, randomised, open-labelled, two-armed study in adults with type 2 diabetes conducted at primary care practices in Sweden. Periodic CGM group- Intervention group: The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system 2 will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-care management of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning. Self-monitoring of blood glucose, SMBG and usual care - Control Group The participants in the control group perform SMBG testing as usual including fasting, pre- or post-prandial measurements. They also receive usual care which comprises consultation with physician diabetes specialist or diabetes nurse depending on individual health care needs.

Interventions

BEHAVIORALPeriodic CGM group with data analysis report- Intervention group

The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.

Sponsors

Sophiahemmet University
Lead SponsorOTHER
Swedish Diabetes Foundation
CollaboratorUNKNOWN
OneTwo Analytics AB
CollaboratorUNKNOWN
Sophiahemmet
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 18-80 years * Type 2 diabetes with a duration of \> 6 months * HbA1c 45-70 mmol/mol * Have a smartphone * Experience of self-monitoring of blood glucose prior to the study start

Exclusion criteria

* Prandial insulin * Pregnancy or planning pregnancy during the study * Breastfeeding * Renal disease with estimated glomerular filtration rate (eGFR) \<45 mL/ min/1.73 m2 * Active malignancy or under investigation for malignancy * Severe visual impairment * Severe skin allergy that inhibits the use of a continuous glucose monitoring device * Glucocorticoids (systemic) * Planned or currently using weight reduction medications, programs, or surgery * Cognitively or psychologically unable to participate and read instructions * Enrolled in other clinical trials * Eating disorders

Design outcomes

Primary

MeasureTime frameDescription
HbA1cchange at week 16mmol/mol

Secondary

MeasureTime frameDescription
Percentage of time spent in range (Glucose)change first 28 days in the study compared with the last 28 days3.9-10 mmol/l as analyzed by OneTwo Analytics CE marked Decision support Clinic
Percentage time spent in hyperglycaemiachange first 28 days in the study compared with the last 28 days\> 10 mmol/L as analyzed by OneTwo Analytics CE marked Decision support Clinic
Percentage time spent in hypoglycaemiachange first 28 days in the study compared with the last 28 days\< 3.9 mmol/L as analyzed by OneTwo Analytics CE marked Decision support Clinic
Average glucose valuechange first 28 days in the study compared with the last 28 daysmmol/L as analyzed by OneTwo Analytics CE marked Decision support Clinic
Standard deviation for glucose valuechange first 28 days in the study compared with the last 28 daysSD as analyzed by OneTwo Analytics CE marked Decision support Clinic
Percentage time in euglycemia, time in targetchange first 28 days in the study compared with the last 28 days3.9-8.0 mmol/L as analyzed by OneTwo Analytics CE marked Decision support Clinic
Number of hyperglycemic episodes per daychange first 28 days in the study compared with the last 28 daysNumber of hyperglycemic episodes per day as analyzed by OneTwo Analytics CE marked Decision support Clinic
Number of hypoglycemic episodes per daychange first 28 days in the study compared with the last 28 daysNumber of hypoglycemic episodes per day as analyzed by OneTwo Analytics CE marked Decision support Clinic
Data availability in % of all timechange first 28 days in the study compared with the last 28 daysData availability in % of all time as analyzed by OneTwo Analytics CE marked Decision support Clinic
Prandial delta within 2 hours, post - pre-prandial values for breakfast, lunch and dinner.change first 28 days in the study compared with the last 28 daysPrandial delta within 2 hours, post - pre-prandial values for breakfast, lunch and dinner as analyzed by OneTwo Analytics CE marked Decision support Clinic
Postprandial peak during 2 hours for breakfast, lunch and dinner.change first 28 days in the study compared with the last 28 daysPostprandial peak during 2 hours for breakfast, lunch and dinner as analyzed by OneTwo Analytics CE marked Decision support Clinic
Night-time insulin effectchange first 28 days in the study compared with the last 28 daysNight-time insulin effect as analyzed by OneTwo Analytics CE marked Decision support Clinic
Fasting glucose levelchange first 28 days in the study compared with the last 28 daysFasting glucose level as analyzed by OneTwo Analytics CE marked Decision support Clinic
The Diabetes Treatment Satisfaction questionnairechange at week 16Includes eight items related to the diabetes treatment over the past weeks.
WHO-5 Well-Being Indexchange at week 16Brief well-being questionnaire with five items in relation to previous 2 weeks
The Patient Preferences for Patient Participation (4Ps)change at week 16The 4Ps is a questionnaire including 12 items comprising patient´s preferences as well as experiences.

Countries

Sweden

Contacts

CONTACTUnn-Britt Johanssson, Professor
unn-britt.johansson@shh.se+4684062902
PRINCIPAL_INVESTIGATORUnn-Britt Johansson

Sophiahemmet University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026